Pazopanib is a new drug used for the treatment of renal cell carcinoma. It belongs to a group of medications called multi-tyrosine kinase inhibitors. Multi-tyrosine kinases are molecules that are responsible for the growth, progression and metastasis of renal cell carcinoma. Treatment of renal cell carcinoma with pazopanib stops the actions of these molecules and help to decrease the progression of the disease. Only advanced renal cell carcinoma is treated with pazopanib. It is made and marketed by GlaxoSmithKline as Votrient.
How is pazopanib administered for the treatment of renal cell carcinoma?
Pazopanib comes in tablet form. The most common starting dose is 800 mg, once a day. It is is taken in empty stomach, one to two hours before eating.
Pazopanib is a tyrosine kinase inhibitor that is used to advanced stages of kidney cancer (metastatic kidney cancer).
How effective is pazopanib treatment in renal cell carcinoma?
The treatment effect of pazopanib for renal cell carcinoma is determined by progression-free survival. In simple terms, progression-free survival is the length of time during and after the treatment the disease does not get worse. Treatment of renal cell carcinoma with pazopanib gives a progression-free survival of approximately 9.2 months. This means the treatment can stop the worsening of renal cell carcinoma for approximately 9.2 months. However, it does not prolong the lifespan of patients.
What are the adverse side effects of pazopanib treatment in renal cell carcinoma patients?
Renal cell carcinoma patients who are treated with pazopanib experience many adverse side effects. This does not mean that all patients who take the medication will experience all of these side effects. These are patient-specific. The general adverse side effects of pazopanib treatment include high blood pressure, liver complications, diarrhea, nausea, anorexia, abnormal heart function, abnormal liver enzymes, stroke and gastrointestinal problems and many more.
How is pazopanib administered for the treatment of renal cell carcinoma?
Pazopanib comes in tablet form. The most common starting dose is 800 mg, once a day. It is is taken in empty stomach, one to two hours before eating.
Pazopanib is a tyrosine kinase inhibitor that is used to advanced stages of kidney cancer (metastatic kidney cancer).
How effective is pazopanib treatment in renal cell carcinoma?
The treatment effect of pazopanib for renal cell carcinoma is determined by progression-free survival. In simple terms, progression-free survival is the length of time during and after the treatment the disease does not get worse. Treatment of renal cell carcinoma with pazopanib gives a progression-free survival of approximately 9.2 months. This means the treatment can stop the worsening of renal cell carcinoma for approximately 9.2 months. However, it does not prolong the lifespan of patients.
What are the adverse side effects of pazopanib treatment in renal cell carcinoma patients?
Renal cell carcinoma patients who are treated with pazopanib experience many adverse side effects. This does not mean that all patients who take the medication will experience all of these side effects. These are patient-specific. The general adverse side effects of pazopanib treatment include high blood pressure, liver complications, diarrhea, nausea, anorexia, abnormal heart function, abnormal liver enzymes, stroke and gastrointestinal problems and many more.
No comments:
Post a Comment